In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

L’Oréal

This article was originally published in The Rose Sheet

Executive Summary

French firm unveils invitroskin.com, a Web site exploring the applications of reconstructed skin in basic research and its role in the development of animal testing alternatives, according to the company. Web site addresses skin engineering and answers questions regarding the development of reconstructed skin and how models can serve as alternatives to animal testing. L'Oréal is committed to the field of reconstituted skin, the firm said, citing the company's organization of the 3rd International Skin Engineering Symposium in Lausanne, Switzerland in October 2004. L'Oréal created skin-science.com in 2002, offering information on reconstructed skin and advice for maintaining healthy skin...

You may also be interested in...



Herbalife 'Just Getting Started' On Growth Following Flat 2019 At $4.9bn Net Sales

"We're a growth company, well-positioned in a global trend of nutrition that the world hasn't seen before," says co-president John Agwunobi. But the direct seller's record volume increase in 2019 didn’t translate to revenue growth as China, Mexico and Central and South America pulled down results.

US FDA Tech Modernization Plan’s Costs Uncertain

Agency officials determining needs using existing budgets before requesting more funds and will engage with tech investors for design advice.

ICER’s Biopharma Members: Why They Joined And What They Get

Biopharma’s funding support for the Institute for Clinical and Economic Review has been slightly above that of payers and providers for the past three to four years.

UsernamePublicRestriction

Register

RS012831

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel